

Index

- A1C, S4, S5, S6, S7, S8, S9, **S16–S18**, S34, S73–S74
 at hospital admission, S211–S212
 at hospital discharge, S217
 cardiovascular disease outcomes and, S77–S78, S138–S141
 confirming the diagnosis, S18
 differences in ethnic populations, S74
 hemoglobinopathies, S16, S17–S18
 HIV and, S23
 in children and adolescents, S20, S23, S74, S183–S185
 in hepatitis C infection, S48
 in hospitalized patients, S212
 in hyperglycemia, S46
 in older adults, S170
 limitations of, S74
 mean glucose and, S74
 microvascular complications and, S75–S76
 other conditions affecting, S18
 periodontal disease and, S49
 physical activity benefits, S60
 in prediabetes, S19–S21
 in pregnancy, S203, S206
 point-of-care assays, S4, S17
 race/ethnicity, S117
 sensory impairment and, S49
 setting individualized goals, S78–S79
 SMBG and, S74
 target in CKD, S154
 testing frequency, S73–S74
 validity in children/adolescents, S20, S23–S24
- acanthosis nigricans, S20, S188
 acarbose, S118
 access to care, S9, S221
 ACCORD BP trial, S127–S128, S153
 ACCORD MIND study, S46, S170
 ACCORD study, S47, S77–S78, S80, S134, S155, S169
 ACE inhibitors, S6, S129, S137, S142
 In children and adolescents, S186–S187, S191
 in CKD patients, **S152–S156**
 in diabetic retinopathy, S156–S158
 for hypertension, S128–S129
 for hyperkalemia and AKI, S130–S131
 in multiple drug therapy, S129
 in pregnancy, S201, S206
- acetaminophen, S87
 acute kidney injury (AKI), S104, S128, S129, S130–S131, S143, **S153**, S215
 ADA evidence-grading system, S2
 ADA Insulin Access and Affordability Working Group, S9
 ADA statements, S1, **S221–S222**
 ADAG study, S74, S79, S80
 adolescents. *See* children and adolescents.
 ADVANCE BP trial, S127
 advocacy statements, S6, **S221–S222**
 aerobic exercise, S36, S57, S60–S62, S171, S181, S182
 affordability, of insulin, S9
 ADA Advocacy statement on, S221
 Affordable Care Act (ACA), S9
 alicercept, S158
 African Americans
 A1C variability in, S17–S18, S74
 BMI cut point in, S23
 exercise targets in, S60
 food insecurity in, S10
 hypoglycemia risk in, S80
 risk-based screening, S22, S23
 age
 A1C and, S17
 in screening and testing, S23
 aging. *See* Older adults
 agricultural workers, migrant and seasonal, S11
 AIM-HIGH trial, S134
 albiglutide, S139, S144–S145, S173
 albuminuria, S59, S62, S80, S126, S128, S129, S131, S136, S145, S152–S156, S185
 alcohol intake, S59, S129
 alogliptin, S118, S138, S145, S214
 alpha-glucosidase inhibitors, S37, S105, S118
 Alzheimer disease, S46, S169
 ambulatory glucose profile (AGP), S75, S76, S88
 amputations, foot, S143, S159, S161–S163
 amylin mimetic, S105, S113, S119
 angiotensin receptor blockers (ARBs), S129
 in acute kidney injury, S131–S132
 in CKD patients, S153
 in diabetic retinopathy, S156, S158
 for hypertension, S131, S156
 in pregnancy, S201, S206
 anti-vascular endothelial growth factor (anti-VEGF) treatment, S158
 antibiotic therapy, S162
 antihyperglycemics, S115
 cardiovascular and cardiorenal outcomes, S6, S138–S139, S141
 selection of, S115
 for type 2 diabetes, S115
 antihypertensives, **S126–S131**
 bedtime dosing, S129
 classes of, S129
 hyperkalemia and AKI, S129, S130–S131
 in diabetics, S130
 initial number of, S129
 lifestyle intervention, S129
 multiple-drug therapy, S129
 in pregnancy, S128–S129, S206
 resistant hypertension, S131
 antiplatelet agents, S6, S135
 antipsychotics, S21, S23, S66, S105
 antiretroviral therapies, S19, S23
 anxiety disorders, S64
 ASCEND trial, S59, S136
 ascorbic acid, S87
 Asian Americans
 BMI cut point, S19, S20, S21, S23, S101, S102, S105–S106
 metabolic surgery in, S106
 risk-based screening, S21, S22, S23
 Aspart, S24, S112, S119, S173
 aspirin
 cardiovascular disease and, S6, S135–S136, S137
 dosing, **S136**
 with P2Y12 receptor antagonist, **S136–S137**
 in people less than 50 years of age, **S136**
 preeclampsia and, S6, **S205–S206**
 resistance, S136
 assisted living facilities, S45, S175, S217
 atenolol, S160, S206
 Atherosclerotic cardiovascular disease. *See* cardiovascular disease
 atorvastatin, S132
 atypical antipsychotics, S21, S23, S65, S66
 atypical diabetes, S26, S46
 autoimmune conditions, S19, **S45**, **S184–S186**, S188
 autoimmune diabetes, S5, S15, S16, S25, S26
 autoimmune markers, S18–S19
 automated insulin delivery, S88, S91, S92, **S93**, S112, S183, S184
 autonomic neuropathy, S61, **S62**, S81, S126, **S159–S160**, S216
- BARI 2D trial, S160
 bariatric surgery, S191, S196
 basal insulin, **S87**, S88, S89, S92, S111, S112, S118, **S120**, S121, S122, S173, S175, S176, S181, S189, S213, S214, S215, S216
 basal insulin analogs, S112, S120
 bedside blood glucose monitoring, **S213**, S216
 behavior change, S4, S9, **S53–S72**
 cardiovascular disease and, S132
 DSMES, **S53–S55**
 in gestational diabetes mellitus, S204
 in hypertension management, S131
 medical nutrition therapy, **S55–S60**
 in obesity management, **S101–S104**
 physical activity, **S60–S62**
 psychosocial issues, **S62–S66**
 smoking cessation, **S62**
 in type 2 diabetes prevention/delay, **S35–S36**
 β -blockers, S45, S129, S137, S142, S161, S206
 β -cell demise/dysfunction, S16
 bevacizumab, S158
 biguanides. *See also* metformin, S118
 bile acid sequestrant, S118
 blood glucose monitoring, bedside, **S213**
 blood glucose self-monitoring (SMBG), S73–S75, S79, S81, S86–S90, S190
 blood pressure targets, S126–S129, S131, S156
 in children/adolescents with type 1, S185–S186, S187, S191–S192
 body mass index (BMI), S19, S20, S23, S24, S25, S35, S36, S37, S46, S60, S61, S101–S102, S105, S106, S188, S191, S205, S207
 bolus calculators, S91
 bone mineral density, S50
 bromocriptine, S118
 bupropion/naltrexone, S103
- calcium channel blockers, S129, S131, S156, S160
 canagliflozin, S118, S120, S141, S142–S143, S144, S145, S155, S156
 cancer, S42, **S45–S46**, S106, S144, S171, S187
 CANVAS trial, S141, S142–S143, S145, S155
 CANVAS-R trial, S143
 capsaicin, topical, S160
 carbamazepine, S160
 carbohydrates, S5, S56, S57, **S58**, S59, S89, S169, S181, S182, S203, S204, S215

- cardiovascular disease, S5-S6, **S125–S150**
 A1C and outcomes of, **S78–S79**
 ACCORD BP study, S127-S128, S153
 ADVANCE study, S127
 antiplatelet agents, **S135–S137**
 aspirin, S135-S137
 blood pressure control, **S126–S131**
 cardiac testing, S138, S142
 glucose-lowering therapies and, S142-S45
 hypertension, **S126–S131**
 intensive vs. standard treatment, S127
 lifestyle intervention, S129, S142
 lipid management, **S131**
 outcomes trials, S138
 pharmacologic interventions, S129-S131, S142
 prevention of, in prediabetes, S3
 risk calculator, S126
 risk management in children/adolescents, S181, **S185–S187**
 screening, S126, S138, S142
 statin treatment, S131-S135
 VADT study, S77, S169
- care delivery systems, S8–S9
 access and quality improvement, S9
 behaviors and well-being, S9
 care teams, S9
 chronic care model, S8
 cost considerations, S9
 telemedicine, S9
- CARMELINA trial, S138, S145
 CAROLINA trial, S6, S138, S142
 Caucasians, S106. *See also* ethnicity
 celiac disease, S19, S45, S184, **S185**
 cerebrovascular disease. *See* cardiovascular disease
- Charcot neuroarthropathy of foot, S62, S161, S162
- childcare settings
 ADA statement on diabetes care in, S221
 children with type 1 diabetes, S80, S182
- children and adolescents, S6, **S180–S199**
 A1C in, S20, S23, S74, S183-S185
 autoimmune conditions, S185-S186
 cardiac function testing, S192
 cardiovascular disease, S192
 cardiovascular risk factor management, S185-S187
 celiac disease, S185
 complications, S191-S193
 DSMES in, S181
 dyslipidemia, S186-S187, S192
 exercise and, S60-S61
 glycemic control, S183-S184
 glycemic targets, S184
 hypertension, S185-S186
 in childcare setting, S182, **S221**
 in school setting, S182, S188, **S221**
 intermittent CGM use in, S89-S90
 lifestyle management, S188–S189
 metabolic surgery, S191
 microvascular complications, S187-S188
 nephropathy, S187, S191
 neuropathy, S187, S191
 nonalcoholic fatty liver disease, S192
 nutrition therapy in, S181
 obstructive sleep apnea, S192
 pharmacologic management, S183-S184, S189-S191
 physical activity and exercise, S181-S182
 polycystic ovary syndrome, S192
 prediabetes in, S19
 psychosocial issues, S182-S183, S192-193
- real-time CGM use in, S89
 retinopathy, S187, S191
 screening and testing, S20, S23-S24, S189
 smoking, S187
 thyroid disease, S184-S185
 transition from pediatric to adult care, S193
 type 1 diabetes in, **S181–S187**
 type 2 diabetes in, **S188–S193**
- CHIPS study, S128
- chronic care model, S7, **S8**, S40, S188
- chronic kidney disease, S6, **S151–S156**
 acute kidney injury, S153
 albuminuria assessment, S152
 cardiovascular disease and blood pressure, S156
 complications, S155
 diagnosis, S152
 epidemiology, S152
 estimated GFR, S152
 glycemic targets, S154
 interventions, S153-S157
 nutrition, S153-S154
 referral to nephrologist, S157
 renal effects of glucose-lowering agents, S154
 risk assessment, S154
 screening, S151
 selection of glucose-lowering agents, S154-S156
 staging, S153
 surveillance, S153
 treatment recommendations, S151-S152
- cigarettes, **S62**, S187, S193
- classification, S4, **S15–S16**
- clonidine, S161, S206
- clopidogrel, S135, S137
- closed-loop pump system, S6, S92, S93, S112, S205
- cognitive impairment, S6, S10, S45, S63-S64, S103,
 dementia and, **S46**
 in hyperglycemia, S46
 in hypoglycemia, S46
 in older adults, S168-170, S171, S174, S175
 lipid-lowering agents and, S135
 statins and, S46
- colesevelam, S118
- community health workers, S11
- community screening, S23
- community support, S11
- comorbidities, S7, S8, S25, S40–S42, S43
 assessment of, **S45–S50**
- computerized physician order entry (CPOE), S212
- CONCEPTT study, S203
- congenital diabetes. *See* neonatal diabetes
- consensus reports, S1–S2
- continuous glucose monitoring (CGM), S5, S6, S86, **S87–S90**, S183, S202
 professional devices, S90
 in children/adolescents, S89, S167, S184, S191
 devices, S87-S90
 education and training, S89
 glycemic control assessment with, S73, S74, **S75**
 in hospitals, S213
 in hypoglycemia prevention, S80–S81
 intermittent, S89-S90
 in older adults, S170, S175
 in pregnancy, **S203**
 real-time, S89
 recommendations, S87-S89
- side effects, S90
 standardized metrics for clinical care, **S76**
- continuous subcutaneous insulin infusion (CSII), S89, S91, S92, S111, S183, S205, S215. *See also* pumps, insulin
- contraception, S104, S105, S183, S187, S200, S201, S202, S206, **S207**
- coronary heart disease. *See* cardiovascular disease
- Coronavirus (SARS-CoV-2), S4, S42, S44, S55, S93
- correctional institutions, ADA statement on diabetes care in, S222
- cost considerations, S4, **S9**, S29, S106, S119
 cost-related medication nonadherence, S4, S9
 counseling, preconception, S182, S183, S193, **S200–S201**
- COVID-19, S4, S42, S44, S55, S93
- CREDESCENCE trial, S6, S141, S143, S145, S155
- cystic fibrosis-related diabetes (CFRD), S4, S15, **S24**
- dapagliflozin, S118, S120, S141, S143, S145, S156
- DASH diet, S35, S129, S131
- DECLARE-TMI trial, S141, S143, S145
- degludec, S112, S119, S120, S121, S174
 degludec/liraglutide, S119, S121
- deintensification of regimens, S171-S172, S174
- delay, type 2 diabetes, S4, S20, S21 **S34–S37**
 cardiovascular disease prevention, S37
 lifestyle interventions, S34–S36
 pharmacologic interventions, S36–S37
- dementia, **S46**, S80, S135, S169. *See also* cognitive impairment/dementia
- dental practices, screening in, S23
- DEPS-R study, S182, S183
- Detemir, S119, S120, S173
- Diabetes Control and Complications Trial (DCCT), S16-S17, S49, S75-S80, S92, S111, S112, S154, S183, S187
- diabetes distress, S5, **S63–S65**, S182, S192
- diabetes plate method, S67
- Diabetes Prevention Program (DPP), S20, S35, S36, S37
- Diabetes Prevention Program Outcomes Study (DPPOS), S21, S35, S37, S59, S115
- diabetes self-management education and support (DSMES), S5, S9
 education and support for, **S53–S55**
 evidence for benefits, S54
 reimbursement, S55
- diabetic ketoacidosis (DKA), S15-S16
 in children with type 1, S181, S184
 in children with type 2, S188, S190
 in hospitalized patients, S216
 in pregnancy, S205
 in type 1 diabetes, S18–S19
- diabetic kidney disease (DKD). *See also* chronic kidney disease.
 exercise in presence of, S62
 protein intake, S59
- Diabetic Retinopathy Study (DRS), S158
- diabetic retinopathy. *See* retinopathy
- diagnosis, S4, **S15–S31**
 A1C, S16–S18
 chronic kidney disease, S152-S153
 confirming, S18
 cystic fibrosis-related diabetes, S24
 fasting and 2-hour plasma glucose, S16
 gestational diabetes mellitus, S27–S29
 monogenic diabetes syndromes, S25–S27
 oral glucose tolerance test, S16

- pancreatic, S27-
posttransplantation diabetes mellitus,
S24-S25
type 1 diabetes, S18-S19
type 2 diabetes and prediabetes, S19-S24
diet, S5, S6, S35, S46. *See also* medical nutrition
therapy
for children and adolescents, S181, S185
for chronic kidney disease, S154-S155
for hypertension, S129
for lipid management, S131
for older adults, S175-176
for pregnancy, S204
for weight loss, **S101-S102**
- digital health technology, **S93**
- dihydropyridine calcium channel blockers, S129,
S130, S131, S156
- diltiazem, S206
- discharge planning, S212, S217
- diuretics, S23, S128, S129, S130, S152, S153
- DKA. *See* diabetic ketoacidosis.
- domperidone, S161
- dopamine-2 agonist, S118
- DPP-4 inhibitors, S6, S114, S115, S116, S118,
S121, S138, S142, S144-S145, S172-S173
- driving, S81, S86, S183
ADA statement on diabetes and, **S222**
- droxidopa, S160
- dulaglutide, S118, S120, S139, S144-S145
- duloxetine, S159, S160
- dying patients, end-of-life/palliative care, S171,
S176
- dyslipidemia, S20, S21, S37, S46, S61, S105, S125,
S126, S133, S136, S157, S171
prevention and management, **S192**
testing, **S186**
treatment, **S186**
- e-cigarettes, S62, S170
- eating disorders, **S65**, S166, S181, S182, S183,
S193
- eating patterns, S35, S41, **S55-S57**, S58, S59, S63,
S189, S207
- EDIC study, S49, S76, S77, S78, S80, S154
- electrocardiogram, S137, S138, S192, S202
- ELIXA trial, S139, S140, S144
- EMPA-REG OUTCOME trial, S141, S142, S145
- empagliflozin, S118, S120, S141, S142, S144,
S145, S155, S156
- employment, ADA statement on diabetes and,
S222
- enalapril, S160
- end-of-life care, S170-S171, **S176**
- end-stage renal disease, S74, S78, S138, S140,
S143, S152, S171, S174
- enteral/parenteral feedings, S6, S215-S216
- epidemiology, of diabetes and CKD, **S152**
- eplerenone, S157
- erectile dysfunction, S49, S159, **S161**
- ertugliflozin, S118
- erythromycin, S161
- ETDRS study, S158
- ethnicity, S17, S18, S23. *See also* specific
ethnicities
- evidence-grading system, S2, S20
- EXAMINE trial, S138, S145
- exenatide, S113, S118, S139, S144-S145
- exercise. *See* physical activity
- exocrine pancreas disease, S15-S16, S26, **S27**,
S48
- EXSCCEL trial, S139, S140, S144
- ezetimibe, S132, **S133**, S135, S141
- family planning, S46, S200, S201, S207
- fasting plasma glucose (FPG) test, S16, S17, S19,
S21, S79, S188, S201, S206
- fats, dietary, S5, S56, **S59**, S186, S192, S204
- fenofibrate, S134
- fibrates, **S134**, S192
- finerenone, S156
- first-degree relatives, with diabetes, S16, S21
- fluvastatin, S132
- food insecurity, S10
- foot care, S6, **S161-S167**
evaluating for loss of protective sensation,
S161-162
evaluating for peripheral arterial disease,
S162
patient education, S162
recommendations, **S161**
revisions summary, S6
treatment, S162
ulcers, S61, S62, S162
- fractures, **S49**, S143, S173, S174
- FRAX score, S49
- GAD autoantibodies, S18
- galactose, S87
- gastroparesis, S159, **S160-S161**
- gemfibrozil, S134
- genetic carrier status, S202
- genetic counseling, S25, S26
- genetic disorders, S27, S45
- genetic factors, S16, S17, S18, S19, S21, S74
- genetic testing, S25, S26
- gestational diabetes mellitus (GDM), **S27-S29**,
S36, S37, S203, **S204-S205**, **S206-S207**
definition, S27
diagnosis, S27-S28
future considerations, S29
glucose monitoring, S203-S204
initial testing, S206
lifestyle management, S36, S204
lifelong testing after, S20
management of, **S204-S205**
medical nutrition therapy, S204
one-step strategy, S28
pharmacologic therapy, S37, S204
postpartum follow-up, S206
postpartum conversion to type 2,
S206-S207
risks in women with prior, S21
screening, S86
two-step strategy, S28-S29
- GI surgery. *See* metabolic surgery
- glargine, S112, S119, S120, S121, S173
- glargine/lixisenatide, S119
- glimepiride, S118, S138, S142, S172
- glinides, S118
- glipizide, S118, S172
- glomerular filtration rate (GFR), S25, S59, S114,
S115, S116, S129, S131, S137, S138, S140,
S141, S143, S151, **S152-S153**, S154, S172,
S173, S187, S191
- glucagon, S27, S79, **S80**, S81
- glucagon-like peptide 1 (GLP-1) receptor ago-
nists, S5, S48, S65, S77, S104, S105, S113, S115,
S116, S117, S118, S137, S138, S140, S143-
S144, S152, S169, S189, S214
- glucocorticoid therapy, S6, S15, S216
- glucose assessment, using CGM, S75
- glucose management indicator, S75, S76, S203
- glucose meters. *See* self-monitoring of blood
glucose
- glucose monitoring. *See also* self-monitoring
in pregnancy, S203
glulisine, S119, S173
glyburide, S118, S172, S204
glycemic control, S1, S6, S8, S9, S10, S17, S25,
S42, S46, S49, S56, S57, S78
assessment of, **S73-S75**
in diabetic neuropathy, S160
physical activity and, **S61**
real-time CGM impact on, S89
glycemic targets, S5, **S73-S84**
A1C and microvascular complications,
S75-S76
A1C and SMBG correlations, S74
A1C differences in ethnic groups, S74
A1C in children, S74
A1C limitations, S74
assessment of, **S73-S75**
in children/adolescents with type 1 diabe-
tes, S184
in chronic kidney disease, S154
in hospitalized patients, **S212-S213**
hypoglycemia, S79-S81
individualization of, S77, S78, S128
intercurrent illness, S81
in pregnancy, S201-S203
preprandial, S79
guanfacine, S160
- HAPO study, S27, S28, S203
- Harmony Outcomes trial, S139, S140, S144, S173
- Hawaiians, native, S22
- health literacy, S11
- hearing impairment. *See* sensory impairment
- heart failure. *See also* cardiovascular disease
glucose-lowering therapies and, S137,
S144-S145
- hemoglobinopathies, S16, S17, S24, S34, S188
- hepatitis B vaccination, S45, S47, S202
- hepatitis C virus infection, S49, S202
- hip fractures, S49
- Hispanic Americans, S21, S22
- HIV, S4, S15, S23
- HLA-DQ/DR alleles, S18
- homelessness, S10-S11
- hospital care, S6, **S211-S220**
admission considerations, S211-S212
bedside blood glucose monitoring, S213
CGM, S213
critical care settings, S213
delivery standards, S211-S212
diabetes care providers, S212
discharge planning, S216-S217
DKA, S216
enteral/parenteral feedings, S215
glucocorticoid therapy, S216
glucose-lowering treatment in, **S213-S214**
glycemic targets, **S212-S213**
hyperosmolar hyperglycemic state, S216
hypoglycemia in, **S214-S215**
insulin therapy, S213-S214
medical nutrition therapy in, **S215**
medication reconciliation, S217
noninsulin therapies, S214
perioperative care, S216
preventing admissions/readmissions, **S217**
self-management in, **S215**
standards for special situations, **S215-S216**
transition to ambulatory setting,
S216-S217
transitioning IV to SC insulin, S214
type 1 diabetes, S214
- HOT trial, S127

- housing insecurity, S10-S11
HPS2-THRIVE trial, S135
human NPH, S119, S120, S173
human papillomavirus vaccination, S47
human regular insulin, S119, S120, S121, S215-S216
hydralzine, S128
hyperbaric oxygen therapy, S163
hyperglycemia, S6, **S46**
 definition in hospitalized patients, S212
 effects on cognition, S169
 in children and adolescents, S182, S183, S189
 in diabetes diagnosis, S18
 in gestational diabetes mellitus, S27
 in pancreatic diabetes, S27
 with intercurrent illness, S81
 posttransplant, S24-S25
hyperkalemia, S130-S131, S143, S153, S156
hyperosmolar hyperglycemic states, S81, S170, S189, S190, **S216**
hypertension, SS6, S20, S37, **S126-S131**
 in children/adolescents, S185-S186
 intensive versus standard treatment, S127-S128
 lifestyle interventions, S129-
 pharmacologic interventions, S129-S132
 pregnancy and antihypertensives, S128
 resistant, S131
 screening and diagnosis, S126
 treatment strategies, S129-S131
hypertriglyceridemia, S59, S112, S114, S134
hypoglycemia, **S79-S81**
 CGM in prevention, S81
 classification, S80
 effects on cognition, S46
 glucagon for, S79, S80
 glucose for, S79, S80
 hospital management, **S214-S215**
 in older adults, **S169-S170**
 postprandial after RYGB surgery, S107-S108
 predictors of, S215
 prevention, S80-SS81
 real-time CGM impact on, S81
 risk assessment, S45
 symptoms, S79-S80
 treatment, S80
 triggering events, S215-S216
 unawareness, S79
 in young children with type 1 diabetes, S80
- idiopathic type 1 diabetes, S19
illness, intercurrent, S81
immune-mediated diabetes, S18-S20
immunizations, S5, **S42-S45**, S47, S202
impaired fasting glucose (IFG), S16, S17, S20, S21
impaired glucose tolerance (IPG), S17, S20, S21, S34, S104, S204
IMPROVE-IT trial, S133,
incretin-based therapies, S6, S48, S144, **S172-S173**. *See also* DPP4 inhibitors and GLP-1 receptor antagonists
Indian Diabetes Prevention Program (IDPP-1), S37
influenza vaccination, **S42**, S44, S47
inhaled insulin, S91, S112, S119, **S121**
inherited diabetes, S19, S25
injectable therapies, S119-S120, S156, S173, S204
 combination, S121
 for type 1 diabetes, S112
 intensifying to, S117
- inpatient care. *See* Hospital care
insulin, S101, S118
 access and affordability, S221
 analog, S118, S119-S121
 basal, **S87**, S88, S89, S92, S111, S112, S118, **S120**, S121, S122, S173, S175, S176, S181, S189, S213, S214, S215, S216
 concentrated, S121
 human, S119, S120, S121, S215-S216
 median cost of, S119
 physiology in pregnancy, S203
 prandial, S86, S111, S112, S120-S121, S181, S182, S214, S215
insulin delivery, **S90-S93**
 automated systems, S93
 combined pump and sensor systems, S92-S93
 digital health technology, S93
 future of, S93-S94
 inpatient care, S90
 pumps, S91-S93
 syringes and pens, S90-S91
 transitioning from IV to subcutaneous, S214
insulin secretagogues, S45, S56, S61, S80, S105, **S172**
insulin sensitizers, S160
insulin therapy, S111-113
 basal, SMBG in patients using, S87
 carbohydrates intake and, S56, S57
 in critical care setting, S213
 injection technique, S113
 intensifying to injectable, S9, S113, S118, S21
 in noncritical care setting, S213-S214
 in pregnancy, S205
 simplification of, for older adults, S174
 for type 1 diabetes, S214
 for type 2 diabetes, S113-S114
intensification, of insulin treatment, S9, S113, S118, S21
interval, testing, S23
intravenous insulin therapy, S189, S212, S213-S214, S216
intravitreal therapy, S158
islet autoantibody testing, S18, S21
islet autotransplantation, S27, S49
islet transplantation, S5, S80, **S113**
isradipine, S160
- Japanese Americans, S23
juvenile-onset diabetes. *See* Type 1 diabetes.
- KDIGO, S153
ketoacidosis. *See* diabetic ketoacidosis
kidney disease. *See* chronic kidney disease and diabetic kidney disease
Kumamoto study, S76
- L-dopa, S87
labetalol, S128, S206
lactation, **S207**
language barriers, S11
laser photocoagulation surgery, S157, S158
latent autoimmune diabetes in adults, S4, S16
Latinos
 food insecurity in, S10
 migrant farmworkers, S11
 risk-based screening, S20
LEADER trial, S143, S173
- lifestyle management. *See* behavior changes
linagliptin, S118, S138, S142, S145
lipid management, **S131**
 lifestyle intervention, **S131**
 ongoing therapy and monitoring, **S131**
 statins, S132-S134
liraglutide, S37, S46, S104, S113, S118, S120, S139, S143-S145, S155, S173, S189, S190
Lispro, S119, S121, S174
lixisenatide, S118, S119, S121, S131, S144, S145
long-term care facilities, S174, S175, S211
longer-acting insulin analogs, S112, S120
Look AHEAD trial, S49, **S102**, S142, S172
loss of protective sensation (LOPS), S159, **S161-S162**
lovastatin, S132
- macronutrient distribution, S35, S55, S56, S58, S59
macular edema, S157, S158, S172
maturity-onset diabetes of the young (MODY), S16, **S25-S26**, S180, S188
meal planning, **S56-S57**, S58, S202
medical devices, for weight loss, **S105**
medical evaluation, S4-S5, S19, **S40-S52**
 comorbidities assessment, S45-S50
 components of, S41, S43, S45
 immunizations, S42-S45
 in patient-centered collaborative care, S40-S41
 recommendations, S42
 referrals, S42, S46
Medicaid expansion, S9
medical nutrition therapy, **S55-S60**
 alcohol, S59
 carbohydrates, S58
 in children/adolescents with type 1 diabetes, S181
 in chronic kidney disease, S153-S154
 eating patterns, S55-S56
 fats, S60
 in gestational diabetes mellitus, S204
 goals for adults, S55
 in the hospital, S215
 macronutrient distribution, S55
 meal planning, S55-S56
 micronutrients and supplements, S59
 nonnutritive sweeteners, S59-S60
 protein, S58-S59
 recommendations for, S56
 sodium, S59
 in type 2 diabetes prevention/delay, S35
 weight management, S57-S58
medications. *See also* pharmacologic interventions
 considerations in pregnancy, **S206**
 with increased diabetes risk, S23
Mediterranean diet, S46, S56, S57, S59, S131
meglitinides, S45, S118
mental health
 anxiety disorders, S64-S65
 depression, S65
 diabetes distress, S65-S66
 disordered eating behavior, S65
 in metabolic surgery candidates, S64
 psychosocial/emotional distress, S64
 referrals for, S64
 screening, S63
 serious mental illness, S65-S66
metabolic surgery, S57, S64, S101, S102, **S105-S107**
 adverse effects, S106-S107

- in children/adolescents, **S191**
- metformin, S25, S27, S59
- cardiovascular outcomes, S138
- for CKD patients, S155
- for gestational diabetes mellitus, S204
- median monthly cost, S119
- for older adults, S172
- to prevent/delay type 2 diabetes, S36–S37
- for type 1 diabetes, S113
- for type 2 diabetes, S113–S121
- methyl dopa, S128, S206
- metoclopramide, S161
- metoprolol, S160
- micronutrients, S55, S56, S59
- microvascular complications, S5, S6, S8
- S151–S167**
- A1C and, S75–S76
- in children/adolescents with type 1 diabetes, S187
- chronic kidney disease, **S151–S156**
- diabetic retinopathy, **S156–S158**
- exercise in presence of, S62
- foot care, **S161–S162**
- neuropathy, **S158–S161**
- midodrine, S160
- MiG TOFU study, S204
- miglitol, S118
- migrant farmworkers, S11
- mineralocorticoid receptor antagonists, S131, S156
- MiTY study, S205
- MOMPOD study, S205
- monogenic diabetes syndromes, S15–S16, **S25–S26**
- naltrexone/bupropion, S103
- natagliinide, S37, S118
- National CLAS Standards, S11
- National Diabetes Education Program, S8S224
- National Health and Nutrition Examination Survey (NHANES), S17, S49, S188
- National Health Interview Survey, S10
- National Institute of Diabetes and Digestive and Kidney Diseases, S9
- native Americans, S22
- neonatal diabetes, **S15–S16**, S180, S200, S202, S203
- nephropathy. *See also* chronic kidney disease. S21, S138, S140, S141, S143, S155, S157, S202
- prevention and management, **S191**
- screening, **S186**
- treatment, **S187**
- neurocognitive function
- in older adults, **S169**
- neuropathy, diabetic, **S158–S161**
- autonomic, S159
- cardiac autonomic, S159
- in children/adolescents, S189, S191
- diagnosis, S159
- erectile dysfunction, S159
- gastrointestinal, S159
- gastroparesis, S160–S161
- genitourinary, S159–S160
- glycemic control, S160
- neuropathic pain, S160
- orthostatic hypotension, S160
- peripheral, S159
- screening, S158–S159
- treatment, S160
- new-onset diabetes after transplantation, S24
- niacin and statin combination, S134, S135
- NICE-SUGAR study, S212
- nifedipine, long-acting, S128, S206
- nonalcoholic fatty liver disease, **S46, S48, S115, S192, S202, S225**
- nonnutritive sweeteners, S56, **S59–S60**
- nursing homes, **S175–S176**
- nutrition. *See* medical nutrition therapy
- obesity management, S5, **S100–S110**
- approved medications for treatment of, S103–S104, S105
- assessment, **S100–S101**
- behavioral therapy, **S101–S103**
- in children/adolescents, S188–S191
- concomitant medications, **S105**
- diet, **S101–S103**
- glucose-lowering therapy, S105
- in diabetes screening, S24
- lifestyle interventions, **S103**
- medical devices for, **S105**
- metabolic surgery, **S105–S107**, S191
- pharmacotherapy, **S105**
- physical activity, **S101–S103**
- weight loss medication safety and efficacy, S105
- weight management, S57, S60, S188
- obstructive sleep apnea, **S49, S192**
- olanzapine, S66, S109
- older adults, S6, S10, **S168–S179**
- deintensification/deprescribing, S172, S174
- end-of-life care, **S176**
- hypoglycemia in, **S169–S170**
- lifestyle management, **S171–S172**
- neurocognitive function, **S169**
- pharmacologic therapy, **S172–S175**
- simplification of insulin therapy, S174
- in skilled nursing facilities/nursing homes, **S175–S176**
- treatment goals, **S170–S171**
- with type 1 diabetes, **S175**
- one-step strategy, GDM, S28–S29
- oral agents. *See also* specific medications
- SMBG in patients using, S87
- oral glucose tolerance test (OGTT), S16, S17, S19, S21, S24, S26, S27, S28, S79, S188, S204, S206
- organ failure, end-of-life/palliative care, S171, S176
- orlistat, S37, S103
- orthostatic hypotension, S126, S128, S159, **S160**
- P2Y12 receptor antagonist, S135, **S136**
- Pacific Islanders, S22
- pain, neuropathic, S159, **S160, S187**
- palliative care, S170, S175–S176
- pancreas transplantation, S113
- pancreatectomy, S27, S49, S92
- pancreatic-related diabetes, S4, S15–S16, **S27, S212**
- pancreatitis, S4, S15, S27, S48–S49, S104, S134, S144, S192
- parenteral feedings, S6, **S215, S216**
- patch, insulin, S90
- pathophysiology, S6, S180, **S186**
- patient education, S9, S11, S41, S81, S184
- on foot care, **S162**
- patient-centered care, collaborative model, **S40–S42**, S53, S62, S217
- Patient-Centered Medical Home, S9, S217
- PCSK9 inhibitors, S132, **S133–S134**
- pens, insulin, **S90–S91**
- periodontal disease, S23, **S49**
- perioperative care, **S216**
- peripheral arterial disease. S125, S137, S61, **S162**
- peripheral neuropathy, S36, S45, S49, **S62, S92, S158–S161**
- pharmacologic interventions, S5, S111–S124. *See also* specific medications, medication classes.
- approved medications, S113, S115
- assessing safety and efficacy, S115
- for cardiovascular disease, S137–S139
- concomitant medications, S105
- costs of noninsulin medications, S118
- glucose-lowering therapy, S105
- for type 1 diabetes, **S111–S113**
- for type 2 diabetes, **S113–S121**
- for weight loss, S105
- in type 2 diabetes prevention/delay, S36–S37
- selecting drugs for, S115
- phentermine, S103, S105
- phentermine/topiramate, S37, S103
- photocoagulation surgery, S157, **S158**
- physical activity, S6, S21, S23, S35, S41, **S60–S62**
- exercise and children, S60–S61
- frequency and types of, S61
- glycemic control and, S61
- hypoglycemia and, S61–S62
- in children/adolescents with type 1 diabetes, S181–S182
- in obesity management, **S101–S102**
- in type 2 diabetes prevention/delay, S35–S36
- pre-exercise evaluation, S61
- with microvascular complications, S62
- physical inactivity, S20, S46
- pioglitazone, S46, S118
- PIONEER trial, S6, S139–S140, S143
- pitavastatin, S132
- plant-based diet, S35, S57
- pneumococcal pneumonia vaccination, S45, S47
- point-of-care A1c assays, S4, S17
- polycystic ovary syndrome, S20, S21, S192, S202, S204, S205
- population health, S4, **S7–S14**
- care delivery systems, S8–S9
- recommendations, S7
- revisions summary, S4
- social context, S10–S11
- postpartum care, S206–S207
- postsurgical diabetes, S49
- posttransplantation diabetes mellitus, S4, S15, **S24–S25**
- pramlintide, S113, S118, S161
- prandial insulin, S86, S111, S112, S120–S121, S181, S182, S214, S215
- prasugrel, S137
- pravastatin, S132
- prazosin, S206
- preconception counseling, S166, S183–S184
- S182–S183, S193, **S200–S201**
- prediabetes
- children and adolescents, S20
- criteria, S20, S21
- diagnosis, **S19–S20**
- screening/testing, S20, S21–S24
- preeclampsia, S200, S201, S203
- aspirin and, **S205–S206**
- pregabalin, S105, S159, S160
- pregnancy, S6, **S200–S210**
- A1C in, S203

- antihypertensive medications in, S128-S129, S206
- CHIPS study, S128
- continuous glucose monitoring in, **S203-S204**
- contraception after, **S207**
- drug considerations, S206
- gestational diabetes, **S27-S29**, S36, S37, S203, **S204-S205**, **S206-S207**
- glucose monitoring in, S203
- glycemic targets in, S201-S203
- insulin physiology in, S203
- lactation, **S207**
- postpartum care, **S206-S207**
- preconception care, S201
- preconception counseling, S166, S183-S184, S182-S183, S193, **S200-S201**
- preeclampsia and aspirin, **S205-S206**
- with preexisting type 1 diabetes, S205
- with preexisting type 2 diabetes, S205
- real-time CGM in, S90
- preprandial glycemic targets, S79
- prevention, type 2 diabetes, S4, **S34-S39**
- Diabetes Prevention Program, S35
- lifestyle interventions, S34-S36
- of vascular disease and mortality, S37
- pharmacologic interventions, S36-S37
- Professional Practice Committee, S3
- protein, dietary, S35, S55, S56, S57, **S58-S59**, S80, S102, S112, S152, S153, S171, S191
- psychosocial/emotional disorders, S4, **S63-S66**
- anxiety disorders, S65-S66
- in children/adolescents, S182-S183, S192-193
- depression, S66
- diabetes distress, S63-S65
- disordered eating behavior, S66
- referral to mental health specialist, S64
- screening, S63
- serious mental illness, S65-S66
- pumps, insulin, S5, S91-S93
- automated systems, S93
- combined with sensor systems, S92-S93
- do-it-yourself systems, S92
- in older adults, S92
- sensor-augmented, S92
- in type 2 diabetes, S92
- in youth, S92
- quality improvement, S9
- race, S17-S18, S20, S36, S60, S81, S92, S102, S126, S138, S139, S141. *See also specific races*
- ranibizumab, S158
- rapid-acting insulin analogs, S111, S112, S119, S121, S215, S216
- real-time CGM
- in adults, S89
- in children/adolescents, S6, S89, S184
- in pregnancy, S90
- in type 1 diabetes, S170
- in type 2 diabetes, S89
- REDUCE-IT, S59, S134
- referrals
- for eye care, S187
- for initial care management, S4, S46
- for mental health care, S65
- to nephrologist for CKD, S152, S153, **S156**
- reimbursement issues, S37, S54, **S55**
- repaglinide, S24, S118
- resistance exercise, S57, S60, S61
- retinopathy, S21, S43, **S156-S158**
- adjunctive therapy, S158
- anti-VEGF treatment, S158
- in children/adolescents with type 1 diabetes, S187, S191-S192
- exercise in presence of, S61, **S62**
- photocoagulation surgery, S158
- macular edema in, S157, S158
- in pregnancy, S201, S202, S205
- retinal photography, S157-S158
- treatment, S157, S158
- in type 1 diabetes, S58
- in type 2 diabetes, S158
- with chronic kidney disease, S152-S153
- REWIND trial, S144
- risk management, cardiovascular disease, S5-S6, S125-S150
- rosiglitazone, S118
- rosuvastatin, S132, S135
- roux-en-Y gastric bypass, S106
- SARS-CoV-2, S4, S42, S44, S55, S93
- SAVOR-TIMI trial, S138, S144
- saxagliptin, S118, S138, S144-S145, S214
- schizophrenia, S66
- school settings, S80, S181-S183, S188
- ADA statement on diabetes care in, S2221
- scientific evidence-grading system, S2, S55
- scientific review, S2, S4, S5
- screening
- asymptomatic adults, S21-S23
- for cardiovascular disease, **S137**
- children and adolescents, S23-S24
- community, S23
- for prediabetes and type 2 diabetes, S23-S24
- for type 1 diabetes risk, S19
- in dental practices, S23
- in HIV patients, S5
- SEARCH study, S186
- seasonal agricultural workers, S11
- second-generation antipsychotics, S66
- self-management. *See* DSMES
- self-monitoring of blood glucose (SMBG), S73-S74, **S85-S87**
- counterfeit strips, S86
- glucose meter accuracy, S87
- with intensive insulin regimens, S86
- interfering substances for, S87
- meter standards, S86
- optimizing monitor use, S86
- with basal insulin and/or oral agents, S87
- semaglutide, S118, S120, S139-S140, S143-S144, S155-S156, S173
- sensory impairment, S4, **S49**
- SGLT2 inhibitors, S6, S77, S78, S113, S115, S118, S120, S121, S125, S141, **S142**, S144-S145, S153, S154-S156, S169, **S173-S175**, S214, S216
- short-acting insulins, S112, S119, S173, S213
- simvastatin, S132, S133, S134
- sitagliptin, S118, S138, S145
- skilled nursing facilities, S174, **S175**, S217
- sleep, obstructive sleep apnea, **S49**, **S192**
- smoking cessation, S5, **S62**
- e-cigarettes, S62
- in type 2 diabetes prevention/delay, S36
- in those predisposed to diabetes, S37
- in youth, S187
- tobacco, **S62**
- social capital, S11
- social context, S10-S11
- social determinants of health (SDOH), S8, S10-S11
- sodium, S56, **S59**, S129, S154
- spironolactone, S128, S156
- SPRINT trial, S127-S128
- staging, of CKD, S45, S153
- of type 1 diabetes, S17
- statins, S46, **S132-S135**
- in children, S187, S192
- cognition, effects on, S46, S135
- in combination treatment, S133
- ezetimibe and, S133
- fibrates and, S134
- high intensity and moderate therapy, S132
- niacin and, S134
- PCSK9 inhibitors and, S133
- in pregnancy, S187, S201, S206
- primary prevention with, S131-S132
- randomized trials, S119
- risk-based therapy, S132
- secondary prevention with, S132, S133
- in type 1 diabetes, S133
- stroke, S77, S127, S128, S133-S136, S138, S140-S144
- subcutaneous insulin infusion, continuous (CSII), S89, S91, S92, S111, S183, S189, S205, S215
- sulfonylureas, S10, S25, S26, S76, S114, S121, S172, **S204**
- second-generation, S118
- supplements, S56, S59, S202
- surgical treatment, S214
- for type 1 diabetes, **S113**, S137
- metabolic, S100, S105-S106, S191
- SUSTAIN trial, S139, S140, S143, S155
- sweeteners, nonnutritive, S56, **S59-S60**
- syringes, insulin, **S90-S91**
- tai chi, S60, S61
- tapentadol, S160
- technology, S5, **S85-S99**
- for CGM, **S81**, **S87-S90**
- in diabetes prevention/delay, S36
- for insulin delivery, **S90-S93**
- for SMBG, **S85-S87**
- TECOS trial, S138, S145
- TEDDY study, S19
- telemedicine, S9
- temperature, effect on SMBG, S87
- testosterone, low, S5, S49
- tetanus vaccination, S48
- thiazide-like diuretics, S129-S131
- thiazolidinediones, S25, S37, S49, S105, S118, S144, **S172**
- thought disorders, S66
- thyroid disease, S26, S45, **S184-S185**, S201
- ticagrelor, S137
- tobacco use
- smoking cessation, S5, **S62**
- in children/adolescents, S187
- in type 2 diabetes prevention/delay, S36
- topiramate/phentermine, S37, S103
- tricyclic antidepressants, S105, S160, S161
- triglycerides
- elevated, S20, S131, S134, S192
- REDUCE-IT trial, S59, S134
- two-hour plasma glucose (2-h PG), S16, S17, S18, S26, S28
- in prediabetes, S20, S21
- two-step strategy, GDM, S28-S29

- type 1 diabetes, S6
 A1C and cardiovascular disease in, S77
 in children and adolescents, **S181-S187**
 classification, **S15-S16**
 daily insulin requirements, S112
 diagnosis, S18-S20
 idiopathic, S19
 immune-mediated, S18-S19
 in older adults, S175
 insulin therapy, S112-S113
 intermittent CGM in, S90
 noninsulin treatments, S113
 pharmacologic therapy, **S111-S113**
 preexisting, in pregnancy, **S205**
 real-time CGM in children/adolescents,
 S183, S184
 screening for risk, S20
 staging, S17
 surgical treatment, **S113**
- type 2 diabetes, S4, S5
 A1C and cardiovascular disease in, S77-S78
 classification, **S15-S16**
 combination therapy, S114
- diagnosis, S19-S24
 in children and adolescents,
 S188-S193
 initial therapy, S114
 insulin therapy, S113-
 intensifying to injectable therapies, S9,
 S113, S118, S21
 lifestyle management, S171-S172
 metabolic surgery, S105-S107
 pharmacologic therapy, **S113-S121**
 postpartum conversion of GDM to,
 S206-S207
 preexisting, in pregnancy, **S205**
 prevention/delay, **S34-S39**
 screening/testing, **S20-S22**, S171
- tyrosine phosphatases, S18
- U-300 glargine, S113, S119, S120, S121, S173,
 S214
- UK Prospective Diabetes Study (UKPDS), S76-S79
 S142
- uric acid, S87
- vaccinations, S4, S42-S46, S201
- vascular dementia, S46, S169
- vegetarian diet, S35, S57
- venlafaxine, S160
- VERIFY trial, S114
- Veterans Affairs Diabetes Trial (VADT), S77, S169
- water intake, S56, S60
- weight loss. *See* obesity management
- well-being, S9, S53-S72
- whites. *See* Caucasians
- wound care, for diabetic foot infections, S162
- xylose, S87
- yoga, S60-S61
- zinc transporter 8, S18
- zoster vaccination, S48